Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats.

Pentel PR, Raleigh MD, LeSage MG, Thisted T, Horrigan S, Biesova Z, Kalnik MW.

BMC Biotechnol. 2018 Jul 24;18(1):46. doi: 10.1186/s12896-018-0457-7.

2.

β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.

Savvidou I, Khong T, Cuddihy A, McLean C, Horrigan S, Spencer A.

Mol Cancer Ther. 2017 Sep;16(9):1765-1778. doi: 10.1158/1535-7163.MCT-16-0624. Epub 2017 May 12.

3.

Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations.

Horrigan SK, Courville P, Sampey D, Zhou F, Cai S; Reproducibility Project: Cancer Biology.

Elife. 2017 Jan 19;6. pii: e21634. doi: 10.7554/eLife.21634.

4.

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Horrigan SK; Reproducibility Project: Cancer Biology.

Elife. 2017 Jan 19;6. pii: e18173. doi: 10.7554/eLife.18173.

5.

Design, Synthesis, and Biological Evaluation of a Series of Anthracene-9,10-dione Dioxime β-Catenin Pathway Inhibitors.

Soldi R, Horrigan SK, Cholody MW, Padia J, Sorna V, Bearss J, Gilcrease G, Bhalla K, Verma A, Vankayalapati H, Sharma S.

J Med Chem. 2015 Aug 13;58(15):5854-62. doi: 10.1021/acs.jmedchem.5b00460. Epub 2015 Jul 31.

PMID:
26182238
6.

Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells.

Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN.

Leukemia. 2015 Jun;29(6):1267-78. doi: 10.1038/leu.2014.340. Epub 2014 Dec 8.

7.

Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.

Ferguson RJ, McDonald BC, Rocque MA, Furstenberg CT, Horrigan S, Ahles TA, Saykin AJ.

Psychooncology. 2012 Feb;21(2):176-86. doi: 10.1002/pon.1878. Epub 2010 Dec 2.

8.

Genomic-based high throughput screening identifies small molecules that differentially inhibit the antiviral and immunomodulatory effects of IFN-alpha.

Chen B, Zong Q, Cibotti R, Morris C, Castaneda J, Naiman B, Liu D, Glodek A, Sims GP, Herbst R, Horrigan SK, Kiener PA, Soppet D, Coyle AJ, Audoly L.

Mol Med. 2008 Jul-Aug;14(7-8):374-82. doi: 10.2119/2008-00028.Chen.

9.

Prevalence of Salmonella in grade A whole shell eggs in the island of Ireland.

Murchie L, Whyte P, Xia B, Horrigan S, Kelly L, Madden RH.

J Food Prot. 2007 May;70(5):1238-40.

PMID:
17536685
10.

Characterization of frequently deleted 6q locus in prostate cancer.

Sun M, Srikantan V, Ma L, Li J, Zhang W, Petrovics G, Makarem M, Strovel JW, Horrigan SG, Augustus M, Sesterhenn IA, Moul JW, Chandrasekharappa S, Zou Z, Srivastava S.

DNA Cell Biol. 2006 Nov;25(11):597-607.

PMID:
17132090
11.

A novel nuclear protein, 5qNCA (LOC51780) is a candidate for the myeloid leukemia tumor suppressor gene on chromosome 5 band q31.

Hu Z, Gomes I, Horrigan SK, Kravarusic J, Mar B, Arbieva Z, Chyna B, Fulton N, Edassery S, Raza A, Westbrook CA.

Oncogene. 2001 Oct 18;20(47):6946-54.

12.

Human mortalin (HSPA9): a candidate for the myeloid leukemia tumor suppressor gene on 5q31.

Xie H, Hu Z, Chyna B, Horrigan SK, Westbrook CA.

Leukemia. 2000 Dec;14(12):2128-34.

PMID:
11187902
13.

Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.

Westbrook CA, Hsu WT, Chyna B, Litvak D, Raza A, Horrigan SK.

Br J Haematol. 2000 Sep;110(4):847-55.

PMID:
11054067
14.

Myotilin is mutated in limb girdle muscular dystrophy 1A.

Hauser MA, Horrigan SK, Salmikangas P, Torian UM, Viles KD, Dancel R, Tim RW, Taivainen A, Bartoloni L, Gilchrist JM, Stajich JM, Gaskell PC, Gilbert JR, Vance JM, Pericak-Vance MA, Carpen O, Westbrook CA, Speer MC.

Hum Mol Genet. 2000 Sep 1;9(14):2141-7.

PMID:
10958653
15.

Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31.

Horrigan SK, Arbieva ZH, Xie HY, Kravarusic J, Fulton NC, Naik H, Le TT, Westbrook CA.

Blood. 2000 Apr 1;95(7):2372-7.

16.

High-resolution physical map and transcript identification of a prostate cancer deletion interval on 8p22.

Arbieva ZH, Banerjee K, Kim SY, Edassery SL, Maniatis VS, Horrigan SK, Westbrook CA.

Genome Res. 2000 Feb;10(2):244-57.

17.

A radiation hybrid breakpoint map of the acute myeloid leukemia (AML) and limb-girdle muscular dystrophy 1A (LGMD1A) regions of chromosome 5q31 localizing 122 expressed sequences.

Horrigan SK, Bartoloni L, Speer MC, Fulton N, Kravarusic J, Ramesar R, Vance JM, Yamaoka LH, Westbrook CA.

Genomics. 1999 Apr 1;57(1):24-35.

PMID:
10191080
18.

Use of a CEPH meiotic breakpoint panel to refine the locus of limb-girdle muscular dystrophy type 1A (LGMD1A) to a 2-Mb interval on 5q31.

Bartoloni L, Horrigan SK, Viles KD, Gilchrist JM, Stajich JM, Vance JM, Yamaoka LH, Pericak-Vance MA, Westbrook CA, Speer MC.

Genomics. 1998 Dec 1;54(2):250-5.

PMID:
9828127
19.

Exclusion of identified LGMD1 loci from four dominant limb-girdle muscular dystrophy families.

Speer MC, Vance JM, Lennon-Graham F, Stajich JM, Viles KD, Gilchrist JM, Nigro V, McMichael R, Chutkow JG, Bartoloni L, Horrigan SK, Westbrook CA, Pericak-Vance MA.

Hum Hered. 1998 Jul-Aug;48(4):179-84.

PMID:
9694248
20.

Modification of bacterial artificial chromosome clones using Cre recombinase: introduction of selectable markers for expression in eukaryotic cells.

Kim SY, Horrigan SK, Altenhofen JL, Arbieva ZH, Hoffman R, Westbrook CA.

Genome Res. 1998 Apr;8(4):404-12.

21.

Evidence for anticipation in autosomal dominant limb-girdle muscular dystrophy.

Speer MC, Gilchrist JM, Stajich JM, Gaskell PC, Westbrook CA, Horrigan SK, Bartoloni L, Yamaoka LH, Scott WK, Pericak-Vance MA.

J Med Genet. 1998 Apr;35(4):305-8.

22.

The Smad5 gene is involved in the intracellular signaling pathways that mediate the inhibitory effects of transforming growth factor-beta on human hematopoiesis.

Bruno E, Horrigan SK, Van Den Berg D, Rozler E, Fitting PR, Moss ST, Westbrook C, Hoffman R.

Blood. 1998 Mar 15;91(6):1917-23.

23.

Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34.

Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov AV.

Somat Cell Mol Genet. 1997 May;23(3):233-6.

PMID:
9330636
24.

Chromosome 8 Losses in Colorectal Carcinoma: Localization and Correlation With Invasive Disease.

Takanishi DM Jr, Kim SY, Kelemen PR, Yaremko ML, Kim AH, Ramesar JE, Horrigan SK, Montag A, Michelassi F, Westbrook CA.

Mol Diagn. 1997 Mar;2(1):3-10.

PMID:
10462585
25.

Construction and use of YAC contigs in disease regions.

Horrigan S, Westbrook C.

Methods Mol Biol. 1997;68:123-36. No abstract available.

PMID:
9055253
26.
27.

alpha 1-Adrenoceptors on rabbit aortic smooth muscle cells in culture and in experimental intimal thickening.

Manderson JA, Hayward IP, Pak E, Horrigan S, Hanley GE, Stephenson JA, Brown L, Campbell JH, Campbell GR.

Clin Exp Pharmacol Physiol. 1995 Dec;22(12):912-8.

PMID:
8846512
28.

Report and abstracts of the second international workshop on human chromosome 8 mapping 1994. Oxford, United Kingdom, September 16-18, 1994.

Spurr NK, Blanton S, Bookstein R, Clarke R, Cottingham R, Daiger S, Drayna D, Faber P, Horrigan S, Kas K, et al.

Cytogenet Cell Genet. 1995;68(3-4):147-64. No abstract available.

PMID:
7842731
29.

Protooncogene c-ski is expressed in both proliferating and postmitotic neuronal populations.

Lyons GE, Micales BK, Herr MJ, Horrigan SK, Namciu S, Shardy D, Stavnezer E.

Dev Dyn. 1994 Dec;201(4):354-65.

30.

Characterization of an associated microfibril protein through recombinant DNA techniques.

Horrigan SK, Rich CB, Streeten BW, Li ZY, Foster JA.

J Biol Chem. 1992 May 15;267(14):10087-95.

31.

Oxidation of beta-very low density lipoprotein by endothelial cells enhances its metabolism by smooth muscle cells in culture.

Horrigan S, Campbell JH, Campbell GR.

Arterioscler Thromb. 1991 Mar-Apr;11(2):279-89.

PMID:
1900191
32.

Direct determination of nitrification in marine waters by using the short-lived radioisotope of nitrogen, N.

Capone DG, Horrigan SG, Dunham SE, Fowler J.

Appl Environ Microbiol. 1990 Apr;56(4):1182-4.

33.

Arterial smooth muscle. A multifunctional mesenchymal cell.

Campbell GR, Campbell JH, Manderson JA, Horrigan S, Rennick RE.

Arch Pathol Lab Med. 1988 Oct;112(10):977-86. Review.

PMID:
3052359
34.

Synthesis of soluble and insoluble elastins in cultures of chick aortic cells.

Foster JA, Rich CB, Horrigan S, Miller M, Dadd CA, Baule V, Keene DR.

Lab Invest. 1988 Jun;58(6):667-73.

PMID:
3379914
35.

Effect of endothelium on beta-VLDL metabolism by cultured smooth muscle cells of differing phenotype.

Horrigan S, Campbell JH, Campbell GR.

Atherosclerosis. 1988 May;71(1):57-69.

PMID:
3377880
36.

Tropoelastin synthesis in fetal bovine tissues.

Foster JA, Rich CB, Horrigan SK.

Coll Relat Res. 1986 Dec;6(5):387-96.

PMID:
3545660
37.

Automated donor-recipient identification systems as a means of reducing human error in blood transfusion.

Sherer PB, Chambers RW, Taswell H, Altshuler C, Aster R, Covino K, Gordon S, Gajewski M, Smith A, Horrigan S, Pfaff K.

Transfusion. 1977 Nov-Dec;17(6):586-97.

PMID:
595113

Supplemental Content

Loading ...
Support Center